or Try an Advanced Search...

    Intravitreal Administration Stocks List

    Symbol Grade Name % Change
    ANNX D Annexon, Inc. 3.15
    APLS F Apellis Pharmaceuticals, Inc. -4.01
    View As Page of Charts
    Related Industries: Biotechnology
    Related Stock Lists: Biopharmaceutical Clinical Medicine Complement System Eye Medicine Acquired Hemolytic Anemia Antibody Autoimmune And Inflammatory Disease Autoimmunity Biomarkers Biotechnology Chronic Obstructive Pulmonary Disease Copd Degenerative Disease Hemoglobin Hemoglobinuria Immune System Immunology Inflammatory Diseases Macular Degeneration

    Related ETFs - A few ETFs which own one or more of the above listed Intravitreal Administration stocks.

    Symbol Grade Name Weight
    BBP D BioShares Biotechnology Products Fund 2.07
    BTEC D Principal Healthcare Innovators Index ETF 1.49
    LABD B Direxion Daily S&P Biotech Bear 3X Shares 1.24
    JFWD D Jacob Funds Inc. Jacob Forward ETF 1.06
    FTHI C First Trust High Income ETF 0.96
    View all Intravitreal Administration ETFs...
    Compare ETFs
    Compare BBP to JFWD Compare BBP to LABD Compare BTEC to FTHI

        Intravitreal Administration Stocks Recent News

        Date Stock Title
        Apr 25 ANNX Down -43.02% in 4 Weeks, Here's Why You Should You Buy the Dip in Annexon (ANNX)
        Apr 23 APLS Apellis Pharmaceuticals to Host Conference Call on May 7, 2024, to Discuss First Quarter 2024 Financial Results
        Related Industries: Biotechnology
        Related Stock Lists: Biopharmaceutical Clinical Medicine Complement System Eye Medicine Acquired Hemolytic Anemia Antibody Autoimmune And Inflammatory Disease Autoimmunity Biomarkers Biotechnology Chronic Obstructive Pulmonary Disease Copd Degenerative Disease Hemoglobin Hemoglobinuria Immune System Immunology Inflammatory Diseases Macular Degeneration
        Intravitreal Administration

        Intravitreal administration is a method of delivering medication directly into the vitreous humor of the eye. This method is used to treat a variety of eye conditions, including age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion. The medication is injected directly into the eye, bypassing the blood-retinal barrier and allowing for a higher concentration of the medication to reach the retina.

        Browse All Tags